Skip to Main Content

Paper Details

SARS-CoV-2 mRNA Vaccine Development Enabled by Prototype Pathogen Preparedness.
bioRxiv
83
2020
CD8, CD8 T cell, COVID-19, CoV-2, CoV-2 spike trimer, SARS, SARS-, SARS-CoV-2, SARS-CoV-2 mRNA, SARS-CoV-2 sequences, betacoronavirus, betacoronavirus spike proteins, mRNA, mRNA-1273, mice
Author NameAffiliation
Sarah R LeistDepartment of Epidemiology University of North Carolina at Chapel Hill Chapel Hill
Alexandra Sch??ferDepartment of Epidemiology University of North Carolina at Chapel Hill Chapel Hill
Stephen D SchmidtVaccine Research Center National Institute of Allergy and Infectious Diseases National Institutes of Health Bethesda
Lingshu WangVaccine Research Center National Institute of Allergy and Infectious Diseases National Institutes of Health Bethesda
Laura J StevensVanderbilt University Medical Center
Mark K LouderVaccine Research Center National Institute of Allergy and Infectious Diseases National Institutes of Health Bethesda
Ande WestDepartment of Epidemiology University of North Carolina at Chapel Hill Chapel Hill
Nicole A Doria-RoseVaccine Research Center National Institute of Allergy and Infectious Diseases National Institutes of Health Bethesda
Guillaume B E Stewart-JonesModerna Inc.
Jason S McLellanDepartment of Molecular Biosciences University of Texas at Austin Austin
Mark R DenisonVanderbilt University Medical Center
James D ChappellVanderbilt University Medical Center
John R MascolaVaccine Research Center National Institute of Allergy and Infectious Diseases National Institutes of Health Bethesda
Ralph S BaricDepartment of Epidemiology University of North Carolina at Chapel Hill Chapel Hill
Ralph S BaricUniversity of North Carolina at Chapel Hill Chapel Hill
Ralph S BaricDepartment of Epidemiology University of North Carolina at Chapel Hill Chapel Hill
Ralph S BaricUniversity of North Carolina at Chapel Hill Chapel Hill
  • 1 - 17

Datasets